Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran
Background and Purpose: Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2016-10-01
|
| Series: | Case Reports in Neurology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/452096 |
| _version_ | 1819236773037867008 |
|---|---|
| author | Valentin Held Philipp Eisele Christoph C. Eschenfelder Kristina Szabo |
| author_facet | Valentin Held Philipp Eisele Christoph C. Eschenfelder Kristina Szabo |
| author_sort | Valentin Held |
| collection | DOAJ |
| description | Background and Purpose: Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. Methods: We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. Results: In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. Conclusions: In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations. |
| first_indexed | 2024-12-23T13:09:45Z |
| format | Article |
| id | doaj.art-6531e081732f4efbb427188544d66cd8 |
| institution | Directory Open Access Journal |
| issn | 1662-680X |
| language | English |
| last_indexed | 2024-12-23T13:09:45Z |
| publishDate | 2016-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Neurology |
| spelling | doaj.art-6531e081732f4efbb427188544d66cd82022-12-21T17:45:46ZengKarger PublishersCase Reports in Neurology1662-680X2016-10-018322422810.1159/000452096452096Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with DabigatranValentin HeldPhilipp EiseleChristoph C. EschenfelderKristina SzaboBackground and Purpose: Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. Methods: We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. Results: In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. Conclusions: In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.http://www.karger.com/Article/FullText/452096Intracerebral hemorrhageAnticoagulantDabigatranIdarucizumabAntidoteStroke |
| spellingShingle | Valentin Held Philipp Eisele Christoph C. Eschenfelder Kristina Szabo Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran Case Reports in Neurology Intracerebral hemorrhage Anticoagulant Dabigatran Idarucizumab Antidote Stroke |
| title | Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran |
| title_full | Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran |
| title_fullStr | Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran |
| title_full_unstemmed | Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran |
| title_short | Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran |
| title_sort | idarucizumab as antidote to intracerebral hemorrhage under treatment with dabigatran |
| topic | Intracerebral hemorrhage Anticoagulant Dabigatran Idarucizumab Antidote Stroke |
| url | http://www.karger.com/Article/FullText/452096 |
| work_keys_str_mv | AT valentinheld idarucizumabasantidotetointracerebralhemorrhageundertreatmentwithdabigatran AT philippeisele idarucizumabasantidotetointracerebralhemorrhageundertreatmentwithdabigatran AT christophceschenfelder idarucizumabasantidotetointracerebralhemorrhageundertreatmentwithdabigatran AT kristinaszabo idarucizumabasantidotetointracerebralhemorrhageundertreatmentwithdabigatran |